Is Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock a Good Buy Or Sell After The Recent Correction?
Abeona Therapeutics Inc. (NASDAQ: ABEO) stock is down 13% in a month. However, the company recently reported encouraging ABO-102 test results in treating Sanfilippo Syndrome. Sanfilippo mainly affects the CNS causing neurological function deterioration. MRI data from Phase 1/2 Transfer A study showed that ABO-102 increased corpus callosum, amygdala, and grey matter volumes in three patients with Sanfilippo Syndrome Types A at 24 months relative to patients that didn’t receive…